Recurrent Islet Cell Carcinoma Recruiting Phase 1 / 2 Trials for Temozolomide (DB00853)

IndicationStatusPhase
DBCOND0028802 (Recurrent Islet Cell Carcinoma)Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs